AstraZeneca’s Imfinzi/Treme Combo Fails To Match Leaders In First-Line Lung Cancer

Too Little, Too Late In Crowded Market

 
• By Andrew McConaghie
  
Astrazeneca
AstraZeneca is the market leader in EGFR-positive lung cancer, but trails far behind Merck and BMS in the PD-1/PD-L1 market.
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip